Document Detail

Recombinant tissue-type plasminogen activators: "time matters".
MedLine Citation:
PMID:  22013562     Owner:  NLM     Status:  In-Data-Review    
Although acute ST elevation myocardial infarction (STEMI) was described nearly a century ago, it remains a major health problem not only in the U.S. but also worldwide with more than three million people suffering STEMI every year. Primary percutaneous coronary intervention (PPCI) is now the treatment of choice for the management of patients with STEMI. In the 20th century, fibrinolytics were the agents of choice for the management of patients with acute STEMI and they continue to be utilized in centers where PPCI facilities are not readily available. Large-scale trials were performed comparing streptokinase and new agents such as the recombinant tissue-type plasminogen activators. This article discusses the use of recombinant tissue plasminogen activators for the management of patients with acute STEMI and the importance of restoring optimal timely reperfusion of the myocardium.
V Kunadian; C M Gibson
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  47     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-10-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  559-70     Citation Subset:  IM    
Copyright Information:
Copyright 2011 Prous Science, S.A.U. or its licensors. All rights reserved.
Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Available therapies and current management of fibromyalgia: Focusing on pharmacological agents.
Next Document:  Difluprednate for inflammatory eye disorders.